Lucy Y Liu1, James P Strassner2, Maggi A Refat2, John E Harris3, Brett A King4. 1. Yale University School of Medicine, New Haven, Connecticut. 2. Department of Dermatology, University of Massachusetts Medical School, Worcester, Massachusetts. 3. Department of Dermatology, University of Massachusetts Medical School, Worcester, Massachusetts. Electronic address: john.harris@umassmed.edu. 4. Department of Dermatology, New Haven, Connecticut. Electronic address: brett.king@yale.edu.
Abstract
BACKGROUND: Vitiligo is an autoimmune disease in which cutaneous depigmentation occurs. Existing therapies are often inadequate. Prior reports have shown benefit of the Janus kinase (JAK) inhibitors. OBJECTIVE: To evaluate the efficacy of the JAK 1/3 inhibitor tofacitinib in the treatment of vitiligo. METHOD: This is a retrospective case series of 10 consecutive patients with vitiligo treated with tofacitinib. Severity of disease was assessed by body surface area of depigmentation. RESULTS: Ten consecutive patients were treated with tofacitinib. Five patients achieved some repigmentation at sites of either sunlight exposure or low-dose narrowband ultraviolet B phototherapy. Suction blister sampling revealed that the autoimmune response was inhibited during treatment in both responding and nonresponding lesions, suggesting that light rather than immunosuppression was primarily required for melanocyte regeneration. LIMITATIONS: Limitations include the small size of the study population, retrospective nature of the study, and lack of a control group. CONCLUSION: Treatment of vitiligo with JAK inhibitors appears to require light exposure. In contrast to treatment with phototherapy alone, repigmentation during treatment with JAK inhibitors may require only low-level light. Maintenance of repigmentation may be achieved with JAK inhibitor monotherapy. These results support a model wherein JAK inhibitors suppress T cell mediators of vitiligo and light exposure is necessary for stimulation of melanocyte regeneration.
BACKGROUND:Vitiligo is an autoimmune disease in which cutaneous depigmentation occurs. Existing therapies are often inadequate. Prior reports have shown benefit of the Janus kinase (JAK) inhibitors. OBJECTIVE: To evaluate the efficacy of the JAK 1/3 inhibitor tofacitinib in the treatment of vitiligo. METHOD: This is a retrospective case series of 10 consecutive patients with vitiligo treated with tofacitinib. Severity of disease was assessed by body surface area of depigmentation. RESULTS: Ten consecutive patients were treated with tofacitinib. Five patients achieved some repigmentation at sites of either sunlight exposure or low-dose narrowband ultraviolet B phototherapy. Suction blister sampling revealed that the autoimmune response was inhibited during treatment in both responding and nonresponding lesions, suggesting that light rather than immunosuppression was primarily required for melanocyte regeneration. LIMITATIONS: Limitations include the small size of the study population, retrospective nature of the study, and lack of a control group. CONCLUSION: Treatment of vitiligo with JAK inhibitors appears to require light exposure. In contrast to treatment with phototherapy alone, repigmentation during treatment with JAK inhibitors may require only low-level light. Maintenance of repigmentation may be achieved with JAK inhibitor monotherapy. These results support a model wherein JAK inhibitors suppress T cell mediators of vitiligo and light exposure is necessary for stimulation of melanocyte regeneration.
Authors: K S Lang; C C Caroli; A Muhm; D Wernet; A Moris; B Schittek; E Knauss-Scherwitz; S Stevanovic; H G Rammensee; C Garbe Journal: J Invest Dermatol Date: 2001-06 Impact factor: 8.551
Authors: Brooke Rothstein; Deep Joshipura; Ami Saraiya; Rana Abdat; Huda Ashkar; Yana Turkowski; Vaneeta Sheth; Victor Huang; Shiu Chung Au; Courtney Kachuk; Nicole Dumont; Alice B Gottlieb; David Rosmarin Journal: J Am Acad Dermatol Date: 2017-04-05 Impact factor: 11.527
Authors: Jillian M Richmond; Dinesh S Bangari; Kingsley I Essien; Sharif D Currimbhoy; Joanna R Groom; Amit G Pandya; Michele E Youd; Andrew D Luster; John E Harris Journal: J Invest Dermatol Date: 2016-09-26 Impact factor: 8.551
Authors: Hideyuki Ujiie; David Rosmarin; Michael P Schön; Sonja Ständer; Katharina Boch; Martin Metz; Marcus Maurer; Diamant Thaci; Enno Schmidt; Connor Cole; Kyle T Amber; Dario Didona; Michael Hertl; Andreas Recke; Hanna Graßhoff; Alexander Hackel; Anja Schumann; Gabriela Riemekasten; Katja Bieber; Gant Sprow; Joshua Dan; Detlef Zillikens; Tanya Sezin; Angela M Christiano; Kerstin Wolk; Robert Sabat; Khalaf Kridin; Victoria P Werth; Ralf J Ludwig Journal: Front Med (Lausanne) Date: 2022-06-09
Authors: Mark G Lebwohl; Emma Guttman-Yassky; Hee J Kim; Ester Del Duca; Ana B Pavel; Giselle K Singer; Brian J Abittan; Margot A Chima; Grace Kimmel; Jennifer Bares; Danielle Baum; Matthew Gagliotti; Jordan Genece; Justin Chu Journal: Arch Dermatol Res Date: 2022-03-13 Impact factor: 3.017